Marshall Wace’s Crinetics Pharmaceuticals CRNX Stock Holding History

Marshall Wace’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.2M	Buy	1,126,639 +442,531	+65%	+$16.4M	0.03%	435
2026 Q1	$24.8M	Buy	+684,108	New	+$30.6M	0.02%	618
2025 Q2	–	Sell	-9,182	Closed	-$308K	–	2777
2025 Q1	$308K	Buy	+9,182	New	+$343K	﹤0.01%	2258
2024 Q3	–	Sell	-141,204	Closed	-$6.32M	–	2575
2024 Q2	$6.32M	Buy	+141,204	New	+$6.52M	0.01%	913
2023 Q4	–	Sell	-29,500	Closed	-$877K	–	2232
2023 Q3	$877K	Buy	+29,500	New	+$608K	﹤0.01%	1542
2022 Q1	–	Sell	-445	Closed	-$12K	–	3447
2021 Q4	$12K	Buy	+445	New	+$11K	﹤0.01%	3740
2020 Q2	–	Sell	-4,246	Closed	-$62K	–	1610
2020 Q1	$62K	Buy	+4,246	New	+$87K	﹤0.01%	1395
2019 Q4	–	Sell	-55,112	Closed	-$829K	–	1754
2019 Q3	$829K	Buy	55,112 +20,874	+61%	+$406K	0.01%	988
2019 Q2	$857K	Buy	34,238 +176	+0.5%	+$4.36K	0.01%	970
2019 Q1	$775K	Buy	+34,062	New	+$837K	0.01%	1013

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's CRNX Position: Q2 2026 in Review

Marshall Wace increased its Crinetics Pharmaceuticals (CRNX) stake by 65% in Q2 2026, buying an estimated $16.4M and bringing the position to 1,126,639 shares worth $42.2M. The position accounts for 0.03% of the portfolio, ranked #435.

Marshall Wace first reported a position in CRNX in Q1 2019 and has held it in 10 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Marshall Wace held 1,126,639 shares of Crinetics Pharmaceuticals worth $42.2M as of Q2 2026.
Marshall Wace bought 442,531 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $16.4M.
Crinetics Pharmaceuticals made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #435 holding.
Marshall Wace first reported a position in Crinetics Pharmaceuticals in Q1 2019 and has held it in 10 quarters since.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.